

Acinetobacter Infections R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/ABC156116C0DEN.html>

Date: October 2020

Pages: 174

Price: US\$ 2,199.00 (Single User License)

ID: ABC156116C0DEN

Abstracts

Acinetobacter Infections Pipeline Overview

The Q4 Acinetobacter Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Acinetobacter Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Acinetobacter Infections Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Acinetobacter Infections disease overview, Acinetobacter Infections types, Acinetobacter Infections symptoms, causes, and FDA/EMA approved treatment options.

Acinetobacter Infections Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Acinetobacter Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.

Acinetobacter Infections Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 46 companies. Business profiles and contact details of the companies actively perusing Acinetobacter Infections pipeline are assessed.

Acinetobacter Infections R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Acinetobacter Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Acinetobacter Infections companies look for licensing and collaboration partners. High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Acinetobacter Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Acinetobacter Infections Pipeline Market News and Developments during 2020

The Acinetobacter Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Acinetobacter Infections Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Acinetobacter Infections pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

46 companies are included including ABAC Therapeutics SA, Acies Bio, d.o.o., AGILeBiotics B.V., AiCuris GmbH & Co KG, Antabio SAS, Appili Therapeutics Inc, Aridis Pharmaceuticals Inc, Armata Pharmaceuticals Inc, AstraZeneca Plc, Atterx Biotherapeutics Inc, Bioharmony Therapeutics Inc, Biological Anti-Infective Medicines LLC, Bugworks Research India Pvt Ltd, Centauri Therapeutics Ltd, ContraFect Corporation, Debiopharm International SA, Destiny Pharma Plc, Eligochem Ltd, EnBiotix Inc, Entasis Therapeutics Inc, F. Hoffmann-La Roche Ltd, Fedora Pharmaceuticals Inc, Hsiri Therapeutics LLC, Inhibrx Inc, KBP BioSciences Co Ltd, Linnaeus Bioscience Inc, Meiji Seika Pharma Co Ltd, Melinta Therapeutics Inc, Mutabilis SA, Neoculi Pty Ltd, Novabiotics Ltd, Octagon Therapeutics Inc, Peptilogics Inc, Pylum Biosciences Inc, Qpex Biopharma Inc, Redx Pharma Plc, RMH Sciences LLC, Sealife PHARMA GMBH, Shanghai Space Peptides Pharmaceutical Co Ltd, Shionogi & Co Ltd, Spero Therapeutics Inc, Summit Therapeutics Plc, VenatoRx Pharmaceuticals Inc, Venus Medicine Research Center, Vitas Pharma Research Pvt Ltd, Xellia Pharmaceuticals ApS,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Acinetobacter Infections pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. ACINETOBACTER INFECTIONS PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Acinetobacter Infections Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Acinetobacter Infections Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Acinetobacter Infections pipeline
- 2.5 Active Companies Developing Acinetobacter Infections pipeline

3. ACINETOBACTER INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. ACINETOBACTER INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

- 4.1 ABAC Therapeutics SA
 - Acies Bio
 - d.o.o.
 - AGILeBiotics B.V.
 - AiCuris GmbH & Co KG
 - Antabio SAS
 - Appili Therapeutics Inc
 - Aridis Pharmaceuticals Inc
 - Armata Pharmaceuticals Inc
 - AstraZeneca Plc
 - Atterx Biotherapeutics Inc
 - Bioharmony Therapeutics Inc
 - Biological Anti-Infective Medicines LLC

Bugworks Research India Pvt Ltd
Centauri Therapeutics Ltd
ContraFect Corporation
Debiopharm International SA
Destiny Pharma Plc
Eligochem Ltd
EnBiotix Inc
Entasis Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Hsiri Therapeutics LLC
Inhibrx Inc
KBP BioSciences Co Ltd
Linnaeus Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Mutabilis SA
Neoculi Pty Ltd
Novabiotics Ltd
Octagon Therapeutics Inc
Peptilogics Inc
Pylum Biosciences Inc
Qpex Biopharma Inc
Redx Pharma Plc
RMH Sciences LLC
Sealife PHARMA GMBH
Shanghai Space Peptides Pharmaceutical Co Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
Summit Therapeutics Plc
VenatoRx Pharmaceuticals Inc
Venus Medicine Research Center
Vitas Pharma Research Pvt Ltd
Xellia Pharmaceuticals ApS

5. ACINETOBACTER INFECTIONS PIPELINE DRUG PROFILES

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

- 5.2.1 Drug
- 5.2.2 Mechanism of Action
- 5.2.3 Phase
- 5.2.4 Co-Developer
- 5.2.5 Originator
- 5.2.6 Synonym
- 5.2.7 Route of Administration
- 5.2.8 Type of Molecule
- 5.2.9 Orphan Drug Status
- 5.2.10 New Molecular Entity
- 5.2.11 Area
- 5.3 Drug Details
- 5.4 Mechanism of Action
- 5.5 Licensing/Collaboration Agreements
- 5.6 Clinical Trial Details

6. ACINETOBACTER INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

- 7.1 About the Publisher
- 7.2 Sources and Research Methodology

I would like to order

Product name: Acinetobacter Infections R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/ABC156116C0DEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABC156116C0DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970